ClinicalTrials.gg
CompletedNCT03607513Updated Feb 3, 2025

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants

A Phase 1 interventional study of JNJ-64264681 and Placebo in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Belgium. Open to participants aged 18 Years to 58 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 58 Years
Sex
All
01

Study summary

The primary purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JNJ-64264681 in healthy participants after single and multiple oral doses.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 58 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have a (BMI) between 18.0 and 30.0 kilogram per meter square (kg/m\^2) (BMI = weight[kg]/height[m]\^2), and a body weight of not less than 50 kilogram (kg)
  • Participant must be healthy on the basis of physical examination, medical history, vital signs, and 12-lead (ECG) performed at screening and Day -1
  • Participant must be healthy on the basis of clinical laboratory tests performed at screening and Day -1. If the results of the serum chemistry panel, coagulation, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not . This determination must be recorded in the participant's source documents and initialed by the investigator
  • Participant must sign an form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
  • Female participants must not be of by fulfilling 1 of the criteria below: a) Be over 45 years of age with no menses for 12 months without an alternative medical cause, with screening follicle stimulating hormone (FSH) levels of greater than (>)40 International Units Per Liter (IU/L) or milli-international units per milliliter (mIU/mL). b) Be permanently surgically sterile. Permanent surgical sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy. Documentation of FSH levels is not required in the case of surgical sterility

Exclusion criteria

Exclusion Criteria:

  • Participant has current, or history of medical illness including, but not limited to, liver or renal insufficiency, significant cardiac (including heart valve disease), vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  • Participant has a history of abnormal bleeding or bruising
  • Participant has a history of atrial fibrillation or history of arrhythmias
  • Participant has history of within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence)
  • Participant has known allergies, , or intolerance to polyethylene glycol 400 (PEG400) (vehicle for JNJ-64264681 for oral solution dosing) for participant in a cohort where study drug is to be dosed as an oral solution, or to microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, silica dioxide, sodium lauryl sulfate, magnesium stearate, or gelatin ( in the solid dose formulation (capsule) of JNJ-64264681) for participant in a solid dose formulation cohort
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose (SAD)

    The SAD part will consist of 6 escalating dose cohorts and 1 fed cohort of healthy male participants, 2 dose escalating cohorts of healthy female participants, and 1 solid dose formulation (capsule) cohort of healthy male participants, who will be dosed after completion of the dose escalation cohorts. Participants in each cohort (except for the solid dose formulation cohort) will receive JNJ-64264681 or Placebo on Day 1, orally. In the solid dose formulation cohort, participants will receive JNJ-64264681 capsule on Day 1. Doses for the female cohorts and fed cohort will be selected based on safety, tolerability, pharmacokinetics (PK),and pharmacodynamic (PD) data from preceding cohorts and the dose for the solid dose formulation cohort will be selected and approximately equal to a dose previously studied in the single ascending dose cohorts.

    Drug: JNJ-64264681 · Drug: Placebo

  • Experimental
    Multiple Ascending Dose (MAD)

    The MAD part will consist of 3 dose escalation cohorts of males and females. Participants will receive once-daily oral doses of JNJ-64264681 or placebo for 10 consecutive days.

    Drug: JNJ-64264681 · Drug: Placebo

Interventions

  • For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.

  • DrugPlacebo

    Matching placebo to JNJ-64264681 will be administered as oral solution.

06

What researchers measure

Primary outcomes

  1. Single Ascending Dose (SAD): Number of Participants with Adverse Events

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Up to Day 14

  2. Multiple Ascending Dose (MAD): Number of Participants with Adverse Events

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Up to Day 24

  3. SAD: Maximum Observed Plasma Concentration (Cmax)

    Cmax is the maximum observed plasma JNJ-64264681 concentration.

    Time frame: Up to Day 4

  4. MAD: Maximum Observed Plasma Concentration (Cmax)

    Cmax is the maximum observed plasma JNJ-64264681 concentration.

    Time frame: Up to Day 13

  5. SAD: Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Tmax is defined as actual sampling time to reach maximum observed concentration.

    Time frame: Up to Day 4

  6. MAD: Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Tmax is defined as actual sampling time to reach maximum observed concentration.

    Time frame: Up to Day 13

  7. SAD: Time to Last Quantifiable Plasma Concentration (Tlast)

    The Tlast is the time to last observed quantifiable plasma concentration.

    Time frame: Up to Day 4

  8. MAD: Time to Last Quantifiable Plasma Concentration (Tlast)

    The Tlast is the time to last observed quantifiable plasma concentration.

    Time frame: Up to Day 13

  9. SAD: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24])

    AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours.

    Time frame: Day 1: Up to 24 hours post-dose

  10. MAD: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24])

    AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours.

    Time frame: Day 1: Up to 24 hours post-dose

  11. SAD: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Observed Quantifiable Concentration (AUClast)

    AUClast is defined as area under the plasma JNJ-64264681 concentration-time curve from time 0 to time of the last observed quantifiable concentration.

    Time frame: Up to Day 4

  12. MAD: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)

    AUCtau is area under the plasma JNJ-64264681 concentration-time curve during a dosing interval (tau) at steady-state.

    Time frame: Day 10

  13. SAD: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])

    The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.

    Time frame: Up to Day 3

  14. SAD: Apparent Elimination Half-life (t1/2)

    t1/2 is apparent elimination half-life of JNJ-64264681 associated with the terminal slope (z) of the semi-logarithmic drug concentration-time curve.

    Time frame: Up to Day 3

  15. MAD: Apparent Elimination Half-life (t1/2)

    t1/2 is apparent elimination half-life of JNJ-64264681 associated with the terminal slope (z) of the semi-logarithmic drug concentration-time curve.

    Time frame: Up to Day 13

  16. MAD: Accumulation Ratio

    MAD: Accumulation Ratio obtained by dividing AUC of JNJ-64264681 at two different time points.

    Time frame: Up to Day 13

07

Study locations

1 site
  • Clinical Pharmacology Unit
    Merksem, 2170, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Aug 2019, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2018
First posted
Jul 31, 2018
StartActual
Jul 31, 2018
Primary completionActual
Aug 9, 2019
CompletionActual
Aug 9, 2019
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03607513
Responsible party
Sponsor
First posted
Jul 31, 2018
Start date
Jul 31, 2018
Primary completion
Aug 9, 2019
Completion
Aug 9, 2019
Last update
Feb 3, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JNJ-64264681

Start the discussion